Sanofi Joins Google’s Verily In Diabetes Venture
Sanofi’s diabetes head says French drug maker’s joint-venture pact with Google’s Verily will combine novel therapies for the condition with cutting edge technologies to produce better focused, outcome-based combinations.
You may also be interested in...
More than 75% of Fortune 500 life-science companies may fall out of that ranking by 2023 amid rising competition from tech giants like Apple, Microsoft and Alphabet, as well as smaller tech players that offer data-driven health services and products that meet the needs of a changing value-based and consumer-driven health-care environment, according to a new Ernst & Young report.
Medtech firms entered 2018 knowing that demands from providers and payers are increasing, the pace of business is quickening, and at the same time patients are more empowered and market access routes are more exacting than ever. Against this backdrop, PwC explains the top health industry issues for the coming year, highlights the forces that will have the most impact on the industry in 2018 and explains why manufacturers need to be nimble.
Q3 medtech financing doubled in dollar volume to $3 billion, with debt offerings again representing the majority of the aggregate; acquisitions totaled $5.3 billion, mainly due to Johnson & Johnson’s $4.3 billion buy of Abbott Medical Optics. Diagnostics financings, which brought in $85 million, continued to decline, but at $5 billion, acquisitions showed a slight increase over the previous quarter, with Danaher’s takeover of Cepheid accounting for most of the M&A volume.